PR Newswire Clinical TrialsOriginal article
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
Phase 2AK146D1IvonescimabPositive
AI Analysis
Summary
Akeso announced first patient dosing in Phase II study (AK146D1-202) of its TROP2/Nectin-4 bispecific ADC combined with Ivonescimab for breast cancer treatment, advancing its IO2.0 and ADC2.0 strategy.
Clinical Trial Data
Phase
Phase 2
Outcome Details
First patient dosed in Phase II study AK146D1-202 evaluating TROP2/Nectin-4 bispecific ADC combined with Ivonescimab
Importance:6/10
Sentiment:
0.60
ADCBispecificOncologyIO2.0_StrategyADC2.0_Strategy
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 10, 2026 4:05 AM